Q&A clinic on Substance, Organisation, Referentials Management Services - January 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 January 2026, 11:00 (CET) to 13 January 2026, 12:00 (CET)

PSUSA/00001503/202504

Human medicines European public assessment report (EPAR): Levetiracetam Actavis, levetiracetam, Date of authorisation: 03/10/2011, Revision: 21, Status: Authorised

Environmental management

PSUSA/00001502/202504

Human medicines European public assessment report (EPAR): Levetiracetam Teva, levetiracetam, Date of authorisation: 25/08/2011, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Levetiracetam Actavis Group, levetiracetam, Date of authorisation: 04/12/2011, Revision: 20, Status: Authorised

Environmental Statement 2024

Human medicines European public assessment report (EPAR): Levetiracetam ratiopharm, levetiracetam, Date of authorisation: 26/08/2011, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Recarbrio, imipenem,cilastatin,relebactam, Date of authorisation: 13/02/2020, Revision: 8, Status: Authorised